Cambridge-Based SynDevRx Achieves Milestone with New Publication on Cancer Drug Conjugate

SynDevRx, Inc., a clinical-stage biotechnology firm in Cambridge, MA, has announced the publication of a scientific paper on its cancer drug, evexomostat/SDX-7320, in Molecular Cancer Therapeutics. The research documents the development of an optimized MetAP2 inhibitor targeting tumors influenced by obesity and metabolic dysfunction. This represents a significant advancement in targeting cancer proliferation through metabolic hormone regulation.

Evexomostat showcases precise targeting of the methionine aminopeptidase 2 (MetAP2) enzyme, essential in tumor growth and angiogenesis. With its sophisticated polymer conjugation technique, SynDevRx improves the drug's safety profile and efficacy, marking a significant improvement over previous MetAP2 inhibitors. This breakthrough could potentially benefit patients with metabolic complications exacerbated by or contributing to their cancer.

The company has successfully moved evexomostat into clinical trials, demonstrating the leadership's commitment to transforming cancer treatment. SynDevRx's approach not only aims at combating the tumor but also addresses the systemic metabolic dysfunction associated with cancer, potentially enhancing patients' quality of life.

With ongoing clinical trials, including the notably collaborative Aretha trial with Memorial Sloan Kettering Cancer Center, SynDevRx is at the forefront of integrating metabo-oncology into cancer care, offering new hope to patients with specific breast cancers and metabolic issues.